Why COSHH-aware inventory discipline matters across collaborating sites
A multi-site research collaboration succeeds only when every site can answer the same basic questions about a vial: what it is, where it came from, how it has been stored, who has access, and which analytical document applies. For UK-sourced research materials, those questions sit inside a COSHH framework, because the Control of Substances Hazardous to Health Regulations require organisations to assess and control exposure risks to hazardous substances used in work. Even where a supplied research peptide is not classified as hazardous under the supplier’s documentation, the inventory still needs a defensible local risk assessment, handling controls, storage conditions and disposal route. The inventory is not a shopping list; it is part of the laboratory’s safety and governance record.
In a multi-site collaboration, the inventory also becomes a shared contract. One site may receive a vial, another may store it, and a third may run the in-vitro assay. Without a harmonised entry, identifiers can drift, CoAs can be detached from the correct batch, and storage histories can become anecdotal. That is why batch-level traceability should be designed into the entry process from the first receipt. The record should link a unique vial identifier to the supplier, catalogue code, label reference, CoA, internal test reference if provided, storage location, quantity, date of receipt and named custodian. The purchaser remains responsible for lawful use, safe handling, storage and disposal, including compliance with COSHH and local laboratory safety standards.
All materials discussed here are research-use-only and are not for human or veterinary use. They are intended for controlled laboratory and analytical research, not for therapeutic, clinical or diagnostic purposes. Any inventory entry should reinforce that restriction, because a co-ordinated record can otherwise imply a form of approval that the supplier and the law do not provide. A short controlled-field statement in the inventory—such as “RUO; not for human or veterinary use; research use only”—is more useful than a verbal reminder.
Building the inventory record: fields, identifiers and documentation
Start with a minimum data set that every site uses. Core fields should include the supplier name, product name, catalogue or SKU code, vial size, physical form, batch or label reference, expiry date, CoA identifier, storage condition, current location, quantity, receipt date, custodian and linked risk assessment. For example, a vial label reference in the format BPC10-03/27 combines a SKU with an expiry month and year; that reference should be recorded exactly and used when querying documentation. Do not rely on cap colour or packaging appearance as an identifier, because the supplier’s own guidance notes that cap colours and packaging may vary and are not indicators of identity, analytical quality or manufacturing origin.
Documentation should be attached to the record rather than stored in a separate folder that nobody can find. Record whether a batch CoA was received, what it covers and where it is held. Research Sciences states that every product includes a CoA for purity and identity by HPLC, and that compounds are independently tested and subject to final UK verification before release. Those statements should be checked against the actual batch document. Purity figures published on a supplier’s homepage—including headline claims of ≥99% verified purity—should be treated as current published wording and reconfirmed on the batch CoA and live site. If an Internal Test Reference (ITR) is quoted, record it, but note that an ITR links to associated sample testing reports and does not confirm that separate deliveries come from the same production lot or have had separate independent testing.
Where the supplier provides safety information or hazard statements, attach or reference them in the COSHH assessment. If no safety data sheet is supplied, record the local risk assessment, handling controls and waste route instead of leaving the field blank. For UK sourcing, check the supplier’s published documentation and current catalogue wording; for example, where the UK supplier’s published pages—such as the Peptide uk listing at Research Sciences—list CoAs and storage guidance, use those as prompts for verification rather than as a substitute for the batch-specific document. The record should also capture any excipient stated by the supplier, such as trace mannitol, and should note that the supplier does not supply blended peptides; if a protocol needs two materials, enter them as separate vials and combine only within a controlled experimental design.
Practical workflow across sites: receipt, storage and reconciliation
On receipt, the designated site should enter the vial into the shared inventory before it is placed in storage. Record the delivery date, tracking reference if used, external condition, label reference, quantity and storage location. Allow vials to reach room temperature before opening in the laboratory workflow, and avoid repeated freeze–thaw cycles. Lyophilised materials should be stored sealed with desiccant, protected from moisture, heat and light, at the temperature stated by the supplier; reconstituted materials are less stable and should be kept at 2–8°C for short-term laboratory use. These are laboratory handling notes, not medical or veterinary instructions. The inventory should show the current storage condition and any movement between freezers, cabinets or sites.
For multi-site work, assign a single custodian at each site and a named reviewer for cross-site reconciliation. A monthly or quarterly check should compare the physical vial against the record, confirm that the CoA still matches the label reference, and flag expired, depleted or quarantined vials. Transfers between sites need a chain-of-custody entry: who released the vial, who received it, the condition on arrival, and any deviation from the expected storage temperature. If a vial is reconstituted for an in-vitro assay, record the diluent volume, concentration and date in the experimental record; use the supplier’s calculator only within laboratory research use and never for dosing. The shared inventory should not contain dosing fields, clinical categories or human-use notes, because those entries would misrepresent the material’s status.
Reconciliation should also cover documentation drift. A restocked product may carry the same ITR as earlier stock, but that does not mean the separate delivery is the same production lot or has had separate independent testing. Record the batch CoA actually received and do not substitute an older certificate because the SKU matches. Retain audit-trail entries for edits, deletions and access changes. At the end of the project, record disposal according to local rules and close the vial record rather than deleting it. Throughout, repeat the controlled statement that materials are not for human or veterinary use and are supplied strictly for controlled laboratory and analytical research. That discipline protects the collaboration’s scientific record and its safety compliance at every site.
